DDInter1607 DDInter484
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Ritonavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Ritonavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) FMO3
FMO3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Almotriptan
Almotriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Amnesia
Amnesia {u} (Side Effect) is caused by {v} (Compound) Ganciclovir
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Ritonavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Ritonavir (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Dasatinib
Ritonavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with FMO3 (Gene) and FMO3 (Gene) is bound by Dasatinib (Compound)
Ritonavir (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Dasatinib (Compound)
Ritonavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Almotriptan (Compound) and Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Ritonavir (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Ritonavir (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Ritonavir (Compound) causes Amnesia (Side Effect) and Amnesia (Side Effect) is caused by Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib